Case Report: Rapid response to gemtuzumab-ozogamicin in a pediatric patient with refractory systemic mastocytosis with AML1::ETO+ acute myeloid leukemia
Song Xue, Man Chen, Hui-Peng Sun, Tong Wang, Li-Na Zhang, Xing-Yu Cao
TL;DR
A 6-year-old child with a rare and resistant form of leukemia showed quick improvement after treatment with gemtuzumab-ozogamicin.
Contribution
This case report highlights the potential of gemtuzumab-ozogamicin as a salvage therapy for refractory systemic mastocytosis with AML1::ETO+ AML.
Findings
Gemtuzumab-ozogamicin induced rapid remission in a pediatric patient with refractory systemic mastocytosis and AML.
Standard salvage treatments failed, but gemtuzumab-ozogamicin was effective in this rare case.
Abstract
This article describes a 6-year-old patient diagnosed with “systemic mastocytosis with AML1::ETO+ AML”, he experience refractory disease during the course of treatment and salvage treatment was ineffective. The patient was administered gemtuzumab-ozogamicin therapy, resulting in rapid remission.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMast cells and histamine · Eosinophilic Disorders and Syndromes · Drug-Induced Adverse Reactions